CELGENE - Core Business + Pipeline Investments = Long Term Growth
Celgene (CELG) reported robust FY11 earnings, despite weak economies and challenging market conditions. Revlimid should drive the growth for the next two-three years through label and geographical expansion and approvals of Pomalidomide (PhIII, RRMM and myelofibrosis) and Apremilast (PhIII) should accelerate the pace further! 2012 will be a defining year for CELG, as multiple approvals and clinical data of its late-stage pipeline are on their way! With Acquisition of Avila therapeutics (pvt. biotech) for $925m for AVL-292 + its proprietary Avilomics platform and strategic equity investment of $15m in Acetylon Corp. (pvt. biopharma), it has invested in Stem cells, Genomics, novel targets and technology platforms to deliver next-generation medicines for hematological malignancies. For more detail, please read our report released on 10th Feb., 2012 on Celgene titled “CELGENE - Core Business + Pipeline Investments = Long Term Growth”.
COMPANIES MENTIONED
CELGENE
CELGENE
